IMSEAR at HELLIS >
Journal of Charoenkrung Pracharak Hospital >
Please use this identifier to cite or link to this item:
|Title: ||Prostaglandins and Hypotensive Lipids|
|Authors: ||Worawan Tantitemit|
|Issue Date: ||30-Sep-2010|
|Publisher: ||Journal of Charoenkrung Pracharak Hospital|
|Citation: ||Journal of Charoenkrung Pracharak Hospital; Volume 5 Number 1 January - June 2009; 29-38|
|Abstract: ||The prostaglandin-related agents, or hypotensive lipids, are a relatively new class of ocular hypotensive agents. Four agents have been approved for clinical use in the United States: two prostaglandin analoques (latanoprost: 1996, travoprost:2001), prostamide (bimatooprost: 2001) and docosanoid (unoprostone: 2000). Latanoprost, which was the first prostaglandinagent for glaucoma treatment, has undergone extensive clinical trials for efficacy, drug interaction and side effects and also has the most extensive clinical experience. The mechanism of action is that these drugs increase uveoscleral outflow by remodeling the extracellular matrix in the uveosscleral outflow pathway which results in increased spaces between the muscle fascicles.Whether there are other mechanisms of action of these drug is not fully understood. The efficacy of latanoprost, travoprost and bimatoprost, that are used once a day, is superior to topical beta-blockers. The drift in effectiveness of intraocular pressure lowering (tachyphylaxis) have not been observed in this drug class, and there is no peak and trough effect. They have mild extraocular irritation, and virtually no systemic side effect.|
|Appears in Collections:||Journal of Charoenkrung Pracharak Hospital|
Files in This Item:
There are no files associated with this item.
Items in IMSEAR Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated.